Page 39 - Patent News Today

The Federal Circuit held in Dynamic Drinkware, LLC v. Nat'l Graphics, Inc., 800 F.3d 1375, 1378 (Fed. Cir. 2015) that for a pre-AIA 35 U.S.C. § 102(e) prior-art reference to be entitled to a provisional...

Drug development in the United States is expensive and time-consuming, which makes pharmaceutical patents an important asset for pharmaceutical companies to protect their investment in bringing new drugs to market.

On February 5, 2024, the USPTO will retire the Electronic Patent Assignment System (EPAS) and the Electronic Trademark Assignment System (ETAS).

Latest news on GMO food, GMO crops, GMO labelling and genetically modified organisms

In GeigTech East Bay v. Lutron Electronics, patent owner GeigTech argued that Lutron should be estopped under 35 U.S.C. § 325(e)(2) from asserting two prior art grounds...

Innovators have long insisted that licensing discussions over standard essential patents (SEP) are one sided: implementers often "hold out" in bad faith by delaying discussions for as long as possible.

The typical flow of prosecution before the U.S. Patent Office begins when the U.S. Examiner issues a First Official Action on the merits.

This is part of a series of articles discussing recent orders of interest issued in patent cases by the United States District Court for the District of Massachusetts.

Sauber says it is not concerned by a report that it could face a fine in Switzerland over its sponsorship deal with online gambling company Stake.

Senator Tammy Baldwin (D-WI) sent letters this week to companies warning of improper Orange Book listings of patents for inhalers...